With four drug candidates, one commencing Phase 3 clinical trial in 2018, Kiniksa Pharmaceuticals (KNSA) seems to be selling the shares at a low price of $17.00-19.00. This amount represents 2.2x its cash per share, which is low as compared to other public competitors researching similar treatments.
In May, remarkable underwriters like Goldman Sachs Group (NYSE:GS) and JPMorgan Chase &....More>>>
A strange thing happens during roaring bull markets. When the economy and stock market are booming, investors seem to forget the fundamentals of stock picking. With nearly every stock being carried higher as the major indexes break record after record, investors think that value no longer matters.
But nothing could be further from the truth. Using fundamentals to locate value stocks works....More>>>
This stock’s low price isn’t going to last forever — it’s time to get in while the getting’s good.
One of the main goals of my premium newsletter High-Yield Investing is stability. I like industries that don’t go through unpredictable hot and cold cycles. Student Transportation (NYSE: STB) is a textbook example.
Large cap funds or mid cap funds? Which fund is ideal for me? This question often comes across most of the investors. If you have been an investor for the last 10-15 years, you will vouch that midcaps have outperformed large caps. However, if you are a recent investor in the last 2-3 months, you must be devastated seeing the performance of the midcap funds.
There are several reasons why investors may want to add gold to their portfolio. Not only can gold rise in value over time, but it can be a hedge against inflation and can add diversification.
Having said that, gold doesn’t fit in to Warren Buffett’s investing philosophy. The central investing principle that has allowed Buffett to build Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B)....More>>>
TransCanada’s (NYSE:TRP) expansion efforts continued paying dividends during the first quarter as earnings and cash flow kept growing. As a result, the Canadian pipeline giant remains on track to achieve its dividend growth targets. CEO Russ Girling affirmed that view on the quarterly conference call, where he detailed the company’s progress on its strategic plan.
It has been some time since I covered casino stocks; not since owning Wynn Resorts (WYNN) off the multi-year lows. Investors that have missed my efforts on these companies should look for more coverage from me in the coming months. Ill be spending several days in Macau in early May before heading to China and Hong Kong to spend some time with industrial suppliers in that region. Its a pilgrimage....More>>>
Global Medical REIT Inc (NYSE:GMRE) has received an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the